Gemcitabine + Carboplatin in Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00450762
Recruitment Status : Completed
First Posted : March 22, 2007
Last Update Posted : March 22, 2007
Eli Lilly and Company
Information provided by:
Ludwig-Maximilians - University of Munich

Brief Summary:
The rational for this trial is given by the knowledge that gemcitabine acts as a potent inhibitor of DNA repair and therefore may prevent adequate repair of platin-induced DNA damage. Gemcitabine is an excellent choice for combination therapy by its unique mechanism of action and favourable toxicity profile. The combination of gemcitabine and cisplatin was shown to be effective in several trials, producing response rates of 30-52 % in patients with pretreated metastatic breast cancer. To improve on tolerability and handling of the regime carboplatin may be the more appropriate choice for treatment. The mechanism of action of carboplatin is very similar to that of cisplatin. The rational for combining gemcitabine and carboplatin is based on their single-agent activities in metastatic breast cancer, the activity of this combination in other malignancies and on the fact that carboplatin has demonstrated efficacy comparable with cisplatin in several tumor types.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: gemcitabine Drug: carboplatin Phase 2

Study Type : Interventional  (Clinical Trial)
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Gemcitabine Plus Carboplatin in Patients With Pretreated Metastatic Breast Cancer
Study Start Date : March 2004
Study Completion Date : October 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female

Inclusion Criteria:

  • Histologically confirmed metastatic breast cancer
  • All patients were required to give written informed consent.
  • Prior treatment with chemotherapy, hormonal therapy, immunotherapy or local radiotherapy was allowed (except gemcitabine or platinum agents).
  • Patients were required to have at least one bidimensionally measurable lesion outside a previous radiation port.
  • Age ≥ 18 years
  • Karnofsky Performance status ≥ 70 %
  • Minimal life expectancy of 12 weeks
  • Adequate haematological, renal, cardiac and hepatic function:

    1. Leukocyte count ≥ 3.0 x 109/l
    2. Absolute neutrophil count ≥ 2.0 x 109/l
    3. Platelet count ≥ 100 x 109/l
    4. Haemoglobin ≥ 8 g/dl
    5. Total serum bilirubin ≤ 1.25 x upper limit of normal (ULN) In presence of liver metastasis ≤ 3 x ULN
    6. Transaminase (ALT,AST) level ≤ 3 x ULN In presence of liver metastasis ≤ 5 x ULN
    7. Alkaline phosphatase level ≤ 2.5 x ULN
    8. Creatinine clearance was required to exceed 60 ml/min.

Exclusion Criteria:

  • Prior treatment with gemcitabine or platinum agents
  • Inadequate creatinine clearance (< 60 ml/min)
  • Only bone metastases
  • Symptomatic brain metastases
  • Women who are pregnant, lactating or refuse effective contraception
  • Secondary malignancy
  • History of another primary malignant disease other than in situ carcinoma of the uterine cervix or adequately treated basal cell skin cancer
  • Active infection
  • Any other concomitant severe clinical condition making implementation of the protocol including pre-hydration difficult.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00450762

Sponsors and Collaborators
Ludwig-Maximilians - University of Munich
Eli Lilly and Company
Principal Investigator: Volker Heinemann, MD University of Munich - Klinikum Grosshadern Identifier: NCT00450762     History of Changes
Other Study ID Numbers: Gem/Carbo MUC01
First Posted: March 22, 2007    Key Record Dates
Last Update Posted: March 22, 2007
Last Verified: March 2007

Keywords provided by Ludwig-Maximilians - University of Munich:

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs